The landscape of health and wellness is undergoing a subtle yet significant shift, with botanical drugs, long overshadowed by their dietary supplement cousins, re-emerging as a focal point for legislative and regulatory bodies. This resurgence is marked by a bipartisan legislative push and proactive engagement from the U.S. Food and Drug Administration (FDA), signaling a potential revitalization of a therapeutic category that has seen limited development.
In a notable move on Capitol Hill, Congresswoman Lauren Boebert (R-CO) introduced the Advancing Botanical Drug Development Act in late August. This proposed legislation aims to bolster intellectual property (IP) protections for botanical drugs, a product development avenue established by the FDA’s Center for Drug Evaluation and Research (CDER) in 2006. While botanicals, like supplements, are derived from plant materials, their classification as drugs sets them apart. Unlike dietary supplements, which are intended to supplement the diet, botanical drugs are rigorously developed and approved by the FDA to diagnose, treat, and prevent specific diseases in humans.
The Advancing Botanical Drug Development Act proposes a 12-year period of market exclusivity for developers of botanical drugs. This incentive is designed to spur increased research and investment in a sector that has, to date, struggled to gain traction compared to the explosive growth and innovation seen in the dietary supplement market over the past two decades. Crucially, lawmakers have emphasized that this bill will not compromise the stringent clinical standards required for botanical drug approval. "Botanical drugs are FDA-approved medicines, not dietary supplements," stated Representative Boebert in a press release accompanying the bill’s introduction. This clarification underscores the distinction the bill seeks to reinforce and protect.
This legislative initiative was quickly followed by a significant step from the FDA itself. Just a week after Representative Boebert’s announcement, the agency opened a public docket to gather input and assess the current state of botanical drug development. This public comment period is scheduled to run until November 3, 2026. The FDA’s initiative follows a productive roundtable discussion hosted by the Reagan-Udall Foundation, an independent organization that supports the FDA’s mission. Further demonstrating a commitment to international collaboration and knowledge sharing, a joint workshop with the European Medicines Agency (EMA) is slated for September 25, 2026. This session aims to examine and learn from the regulatory challenges and successes encountered in the European Union concerning plant-derived medicines.
Marta Sokolowska, Ph.D., Deputy Center Director for Substance Use and Behavioral Health at CDER, highlighted the potential of this field in a statement: "Given that many people use botanicals for self-treatment, botanical drug products represent an area where greater scientific development could create new opportunities for patients." This sentiment suggests an acknowledgment within the regulatory agency of the unmet needs that scientifically validated botanical therapies could address.
A Limited History of Approved Botanical Drugs
The journey of botanical drugs through the FDA’s approval process has been a notably slow one. To date, only four botanical drugs have successfully navigated the rigorous pathways for New Drug Applications (NDAs) and Biologics License Applications (BLAs) in the United States.
- Veregen: This topical treatment for genital warts utilizes sinecatechins, active compounds derived from green tea. It was one of the earlier approvals in this category.
- Mytesi and Fulyzaq: Both of these drugs, approved for the treatment of non-infectious diarrhea in HIV patients, are derived from crofelemer, a compound extracted from the dragon’s blood tree.
- NexoBrid: This biologic is derived from pineapple stems and is used for the removal of dead tissue in burn patients. Its development highlights the potential of enzymatic therapies derived from plants.
- Filzuvez: This treatment for wounds associated with epidermolysis bullosa features birch bark extracts as its active component.
All of these approved botanical drugs are more than a decade old, reflecting the lengthy development timelines characteristic of this sector. For comparison, Qutenza, a topical capsaicin treatment for neuropathic pain, received marketing authorization from the EMA in Europe back in 2009. Additionally, several widely recognized botanicals, such as psyllium and witch hazel, have achieved over-the-counter (OTC) status under established safety monographs, indicating a recognized therapeutic utility but not necessarily the rigorous drug-level approval.
Roy Upton, founder, president, and editor of the American Herbal Pharmacopoeia (AHP), offered a critical perspective on the current state of approved botanical drugs. "Considering there are only four approved botanical drugs over 20 years of the category’s existence, I wouldn’t call that a lot of interest," Upton stated. He further elaborated, "None of these are really botanicals. These are botanical isolates approved for uncommon indications." This critique suggests that the current approved drugs may not fully represent the broader potential of whole-plant or complex botanical preparations, and that the regulatory pathway might be more suited to purified compounds rather than traditional herbal medicines.
European Precedents and Challenges
The European Union offers its own regulatory framework for plant-derived medicines, including a specific marketing authorization pathway. However, this route is rarely utilized, with few companies opting for it due to the substantial clinical requirements and associated high costs. Similar to the situation in the U.S., this category in Europe often finds itself overshadowed by more popular and less regulated schemes, such as those for food supplements and Traditional Herbal Registrations (THR).
Dr. Joerg Gruenwald, founder and chief scientific advisor of the research and consulting firm Analyze & Realize GmbH, observed this disparity. "The supplement category is growing faster in Europe, with lots of new products and innovations," Dr. Gruenwald noted. "In comparison, herbal drugs are much more stagnant." This observation reinforces the idea that the regulatory environment significantly influences the vitality of a product category.
Gruenwald expressed support for initiatives aimed at improving the regulatory landscape for herbal drugs: "I support all initiatives that try to develop better regulations for herbal drugs," he said. "The drug pathway has tough requirements, high investment costs, and a long process for registration. Whether in the US or EU, it will take a lot of money and government support to open an important avenue like this." His statement underscores the significant financial and governmental backing required to make the drug development pathway for botanicals more accessible and appealing.
Shifting Political Winds and Regulatory Modernization
The current legislative and regulatory momentum suggests that botanical drugs are now benefiting from a degree of government support that has historically been elusive. This development occurs against a backdrop of intense interest from the dietary supplement industry, which is actively monitoring a range of legislative proposals aimed at modernizing its own regulatory framework. These proposals include mandatory product registration, expanded access through Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs), federal uniformity in regulation, and the establishment of a self-affirmed Generally Recognized As Safe (GRAS) pathway.
The "modernization" umbrella now appears broad enough to encompass advancements in both supplement and drug regulations, particularly for ingredients that could potentially serve in both capacities. Acting FDA Commissioner Kyle Diamantas, in a statement released during the Trump administration, articulated a commitment to this evolving landscape: "Under the Trump Administration, we are committed to modernizing regulatory frameworks to ensure promising, natural health options are evaluated through rigorous science." He further emphasized, "Botanical drug products represent a critical area where greater scientific development can unlock new therapeutic opportunities for American patients while maintaining the highest safety standards." This indicates a strategic alignment within the FDA to explore and support the scientific validation of plant-derived therapies.
Despite these advancements, botanical products, whether positioned as drugs or supplements, will continue to confront inherent formulation challenges. The biological variability of plant materials, leading to potential inconsistencies in batch-to-batch quality, and the complexities of studying multi-ingredient formulations remain significant hurdles. However, the renewed attention from both Congress and the FDA on this previously quiet sector could indeed catalyze innovation across both the drug and supplement spheres.
The Continuing Trend of Medicalization in Supplements
The growing interest in botanical drugs can be viewed as part of a larger trend towards the "medicalization" of the supplement industry. This trend is also evident in the rise of other product categories like peptides and intravenous (IV) therapies, which are increasingly being explored within or adjacent to the supplement market. This phenomenon raises fundamental questions about the very definition and purpose of dietary supplements.
The core debate revolves around whether these products are intended as food ingredients designed to offer synergistic benefits in small doses, or if they are high-potency isolates engineered to exert more drug-like impacts on human health. Leading trade associations within the supplement industry have vocally advocated for a broader definition of "dietary supplement" that extends beyond traditional food-use parameters as defined by the FDA. However, the ultimate outcome of these advocacy efforts remains uncertain.
What appears more certain is the further blurring of the lines between supplements and drugs if the U.S. government continues to actively support botanical products through either regulatory pathway. Roy Upton of the AHP articulated this definitional challenge: "Unfortunately, in the US, there does not appear to be a threshold where a supplement crosses over into the drug world," he observed. "Internationally, a traditional medicine is defined predominantly as a Galenic preparation, and relatively pure compounds are restricted to conventional drug categories. I don’t know if this is an emerging trend, but it is a foundational, definitional problem within DSHEA [Dietary Supplement Health and Education Act of 1994]."
This ongoing re-evaluation of botanical products, driven by legislative intent and regulatory inquiry, suggests a pivotal moment for the industry. The potential for increased investment and scientific exploration into plant-based medicines is significant, but it will necessitate careful navigation of regulatory distinctions and a commitment to robust scientific validation. The path forward for botanical drugs, while promising, will likely be shaped by the ability to clearly define their therapeutic roles and meet the exacting standards expected of approved medicines.
